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ABSTRACT
Background Cohen syndrome is a rare autosomal
recessive disorder with a complex phenotype including
psychomotor retardation, microcephaly, obesity with
slender extremities, joint laxity, progressive chorioretinal
dystrophy/myopia, intermittent isolated neutropenia,
a cheerful disposition, and characteristic facial features.
The COH1 gene, which contains 62 exons, is so far the
only gene known to be associated with Cohen syndrome.
Point mutations, deletions and duplications have been
described in this gene. Oligonucleotide arrays have
reached a resolution which allows the detection of
intragenic deletions and duplications, especially in large
genes such as COH1.
Method and results High density oligonucleotide array
data from patients with unexplained mental retardation
(n¼1523) and normal controls (n¼1612) were analysed
for copy number variation (CNV) changes. Intragenic
heterozygous deletions in the COH1 gene were detected
in three patients but no such changes were detected in
the controls. Subsequent sequencing of the COH1 gene
revealed point mutations in the second allele in all three
patients analysed.
Conclusion Genome-wide CNV screening with high
density arrays provides a tool to detect intragenic
deletions in the COH1 gene. This report presents an
example of how microarrays can be used to identify
autosomal recessive syndromes and to extend the
phenotypic and mutational spectrum of recessive
disorders.
INTRODUCTION
The phenotype of Cohen syndrome (MIM 216550),
a rare autosomal recessive disorder, has been
described to be fairly homogeneous in Finnish
patients where the founder mutation
c.3348_3349delCT is detected in about 75% of
mutant alleles.1 But in non-Finnish and especially
in young Cohen patients, a high genotypic and
phenotypic variability occurs. Several clinical diag-
nostic criteria for Cohen syndrome have been
introduced.2e5 Chandler et al proposed that, next to
significant learning disabilities, two of the
following criteria should be present for Cohen
syndrome diagnosis: facial gestalt, pigmentary
retinopathy, and neutropenia.3 Kohlemainen et al
suggested Cohen syndrome in patients fulfilling at
least six of the following criteria: developmental
delay, microcephaly, typical facial gestalt, truncal
obesity with slender extremities, overly sociable
behaviour, joint hypermobility, high myopia and/or
retinal dystrophy, and neutropenia.5 El Chehadeh
et al concluded that mutation analysis is not indi-
cated in the absence of chorioretinal dystrophy or
neutropenia.6
The COH1 gene (VPS13B, MIM 607817), so far
the only gene known to be associated with Cohen
syndrome, is one of the largest known genes in the
human genome and comprises 62 exons distributed
along 864315 bp of chromosome 8. More than 96
different mutations in COH1 gene have been
detected in association with Cohen syndrome. The
majority of them are terminating mutations
predicted to result in a functional null allele.5 7e9
Recently large intragenic deletions and duplications
in the COH1 gene have been identified as a cause of
Cohen syndrome.10 11 Molecular diagnosis of
syndromes has been improved by the introduction
of oligonucleotide arrays which have reached
a resolution facilitating the detection of intragenic
copy number variations (CNVs).
ARRAY DATASETS AND METHODS
Array datasets
Recruitment of patients (n¼1523) had been part of
the German Mental Retardation Network
(MRNET) study (http://www.german-mrnet.de/).
In the present study we focus on three patients, in
which CNVs in the COH1 gene were detected. As
a control set, CNV data (n¼1612) had been gener-
ated from the population based KORA study
(Cooperative Health Research in the Augsburg
Region).
CNV analysis
Genome-wide screening for CNVs was performed
using the Infinium Human550 Genotyping Bead-
Chip (Illumina, SanDiego, California, USA) in
patients 1 and 2 and the Genome-Wide Human
SNP Array 6.0 (Affymetrix, Santa Clara, California,
USA) in patient 3. The controls have been investi-
gated with Illumina Infinium Human550-Quad or
Human610-Quad arrays.
The genomic DNA of the patients and controls
was isolated from peripheral blood lymphocytes
according to standard procedures and processed
following the manufacturer ’s instructions. Arrays
were scanned with the Illumina BeadArray Reader
and with the Affymetrix Scanner 3000 7G. Geno-
types were called with the Illumina GenomeStudio
Software or using the Affymetrix Genotyping
Console Software (version 3.0.2), respectively.
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Data analysis of the Illumina arrays was performed according to
Wagenstaller et al.12 CNV profiling of the Affymetrix array data
was accomplished by using the Segment reporting Tools of the
Genotyping Console Software. To determine a deletion we used
as a cut-off the smoothing median of five or more adjacent single
nucleotide polymorphisms (SNPs) with copy number values
#1.5 or with log2 intensity ratios #1 for Illumina and Affy-
metrix arrays, respectively. CNVs with copy number values
$2.5 or with log2 intensity ratios $1 were suspicious for
duplication. All CNVs were checked for gene content and
overlap with known genetic variants as provided by the genome
browser of the University of California Santa Cruz (UCSC)
(http://genome.ucsc.edu, hg 18) and the Database of Genomic
Variants (DGV, http://projects.tcag.ca/variation). CNVs not
annotated as structural polymorphisms and containing RefSeq
genes were genotyped by quantitative PCR (qPCR). Monitoring
of the PCR reaction and setting of baseline and threshold cycle
values were accomplished automatically with the Sequence
Detection System Version 2.3 Software (SDS 2.3, Applied
Biosystems, Darmstadt, Germany). The relative quantification
analysis based on the comparative Ct method was performed
using an in-house developed Perl script.
Sequencing
In the patients with a partial heterozygous deletion of the
COH1 gene, direct sequencing of the entire coding region and
the exon/intron boundaries of COH1 was carried out using
BigDye Ready Terminator Sequencing Kit and an 48 capillary
Abi 3730 Genetic Analyzer (Applied Biosystems) in accordance
with standard procedures. All identified variants were genotyped
in 676 individuals of a population based cohort (KORA-cohort)
via the MassARRAY system (Sequenom genotyping platform)
and the iPLEX Gold chemistry. The assay design used the
AssayDesign 3.1.2.2 software with default parameters. Geno-
type calling was performed by the SpectroTYPER 3.4 software.
Nomenclature
Gene model NM_17890.3/NP_060360 based on UCSC browser
was used to describe the detected COH1 gene variants (http://
genome.ucsc.edu hg18).
Figure 1 Array results and electropherograms of the COH1 mutations in patients 1 to 3. Patient 1 is affected by a 125 kb deletion encompassing
exons 26 to 31 of the COH1 gene (chr.8: 100 563 167.100 642 020) and a missense mutation c.5197C/T of the second allele. In Patient 2 a 156 kb
deletion encompassing exons 16 to 19 of the COH1 gene (chr.8:100 250 047.100 405 623) and a one base pair deletion c.1161delA in the second
allele was detected. In Patient 3 a 315 kb deletion encompassing exons 1 to 17 of the COH1 gene (chr8:100 015 029.100 347 846) and missense
mutation 3866C/G and three base pair insertion c.11827_11828insATG in the second allele were found. CNV, copy number variation.
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RESULTS
Molecular findings
Analysis of SNP oligonucleotide array and subsequent qPCR
discovered CNVs in the COH1 gene in three patients: a maternal
67 kb deletion encompassing exons 26 to 31 of the COH1 gene
(chr8: 100 573 090.100 639 924; c.3871-5024del/p.G1291fsX42)
in patient 1, a paternal 193 kb deletion encompassing exons 9 to
19 of the COH1 gene (chr8: 100 216 034.100 409 167; c.1207-
2824del/p.L403fsX11) in patient 2, and a maternal 315 kb dele-
tion encompassing exon 4 of the OSR2 gene and exons 1 to 17 of
the COH1 gene (chr8:100 015 029.100 347 846; c.1-2515del) in
patient 3 (figure 1). There were no such changes in the 1612
controls.
Sequencing of the COH1 gene identified in patient 1
a paternal missense mutation in exon 32 leading to a stop codon
(c.5086C/T/p.R1696X), in patient 2 a maternal 1 bp deletion
in exon 60 leading to a stop codon (c.11505delA/p.K3835fsX43),
and in patient 3 a heterozygous missense mutation in exon
25 (c.3866C/G/p.T1289S) and a heterozygous three base
pairs insertion in exon 62 (c.11827_11828insATG/p.D3942_
G3943insD), both inherited from the father (figure 1).
These mutations were not present in 676 samples from a
general population cohort (KORA) and not annotated as




The boy was born after an uneventful pregnancy at term as the
first child of unrelated and healthy Arabian parents. Birth
weight, length and head circumference were not recorded. A
delay in motor development became evident within his first year
of life. Sitting started at the age of 18 months, walking at
24 months. A detailed examination at the age of 3 years showed
a hypotonic boy with a height of 79 cm (4.8 SD), a weight of
9300 g (5.2 SD), and a head circumference of 44 cm (4.9 SD).
A delay in speech development as well as in comprehension was
obvious. There was mild craniofacial dysmorphism including
horizontal eyebrows, a broad and downturned nasal tip, a broad
columella, a short philtrum, a thin upper lip, and an everted
lower lip (figure 2). The ophthalmologic examination revealed
bilateral myopia, astigmatism and a slightly increased pigmen-
tation of the retina. There was no neutropenia.
Patient 2
This boy was born at term after an uneventful pregnancy as the
second child of healthy unrelated German parents, with a birth
weight of 2460 g (2.4 SD), a birth length of 46.5 cm (2.3 SD),
and a head circumference of 31.5 cm (2.9 SD). Developmental
milestones were delayed with a sitting age of 12 months and
a crawling age of 17 months. Examination at the age of
Figure 2 Craniofacial phenotype of
patients 1 to 3. Patient 1 at the age of
3 years with horizontal eyebrows,
a broad and down turned nasal tip, a
broad columella, a short philtrum,
a small upper lip and everted lower lip.
Patient 2 at the age of 18 months with
horizontal eyebrows, almond shaped
and downslanting palpebral fissures,
a broad nasal root, a round nasal tip,
thick columella, a short philtrum, and
open appearance of mouth with
prominent upper gingiva. Patient 3 at
the age of 28/12 years with round and
flat face, bushy eyebrows with lateral
flaring, broad nasal bridge, short
philtrum and microtia with overfolded
helices.
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18 months showed a hypotonic toddler with a weight of 10.1 kg
(1.5 SD), a height of 80 cm (1 SD), and a severe microcephaly
with an occipitofrontal circumference (OFC) of 42.5 cm (4.8
SD). Speech development had not occurred but comprehension
was nearly normal. Facial dysmorphism consisted of mild
occipital flattening, horizontal eyebrows, almond shaped
palpebral fissures, a broad nasal root, a round nasal tip, a thick
columella, a short philtrum, an open appearance of the mouth
with a prominent upper gingiva, and a large gap between the
incisors (figure 2). Funduscopy and complete blood count
revealed no abnormalities.
Patient 3
The patient is the second child of a healthy non-consanguineous
German/African couple. The premature birth occurred at
35 weeks of gestation with a birth weight of 2450 g (0.1 SD),
a birth length of 46 cm (0.4 SD), and an OFC of 33.5 cm (0.6
SD). A heart defect (atrioseptal defect (ASD) II and pulmonary
stenosis) and arrhythmia were diagnosed after birth. Develop-
mental delay persisted until 2 years of age and improved after
surgical correction of the heart defect. The patient started to
walk at the age of 24 months and at the age of 23/4 years she
showed normal body measurement with a height of 95 cm (0.4
SD), a weight of 11.5 kg (1.4 SD), and an OFC 50 cm (0.6 SD).
She had a flat face with broad and flat nasal bridge and almond
shaped eyes, a short philtrum with thin vermillion border, and
deep set ears with overfolded helices (figure 2). Funduscopy and
complete blood count revealed normal results.
DISCUSSION
Our report demonstrates that the diagnosis of Cohen syndrome
can be reached in patients with unexplained mental retardation
by applying high resolution oligonucleotide arrays. Although
multiple exon deletions in the COH1 gene have been reported in
single patients,5 7 8 13 the distribution of deletions and dupli-
cations has only been recognised recently.10 11 The frequency of
copy number alterations in the COH1 gene is unknown. Parri
et al disclosed that COH1 CNVs account for 42% of COH1
mutations.11 Balikova et al reported an increase in the detection
rate of 18% (88% instead of 70%) in typical Cohen patients.10
Arrays targeted at individual exons will further increase the
detection rate. We have recently identifieddby molecular
analysisda homozygous 66 kb deletion comprising exons 32
and 33 of COH1 which had escaped detection by current array
comparative genomic hybridisation (CGH) analysis. The fact
that we failed to detect CNVs in the COH1 gene in 1612
controls from a general German population cohort indicates that
CNVs in the COH1 gene are rare. This is in contrast to the
annotation of the COH1 gene CNVs as benign polymorphisms
in the UCSC genome browser and the DGV.
To our knowledge this is the first report on patients with
Cohen syndrome diagnosed by molecular whole genome anal-
yses but not by clinical examination. Cohen syndrome was not
suspected at first instance in the patients, although all of them
were examined by experienced paediatricians or clinical geneti-
cists. This can be explained by the young age of patients
(16 months, 18 months, 23/4 years). The facial appearance of the
infant and young children with Cohen syndrome differs from
adult patients and myopia/retinal pigmentary changes usually
develop in the pre-school age.3 The common facial characteris-
tics in our small series of young patients with Cohen syndrome
were a hypotonic facial expression, almond shaped palpebral
fissures, a prominent nose, and a short philtrum. All patients
were affected by mental retardation and delay in motor and
speech development. Pigmentary retinopathy and neutropenia
were absent in all patients. The unusual phenotype in patient 3
may due to the fact that in addition to exons 1 to 17 of the
COH1 gene, the deletion affected the neighbouring exon 4 of the
ORS2 gene. Although the gene function of ORS2 in humans is
unknown, an influence of the phenotype cannot be ruled out.
In conclusion, the phenotype of Cohen syndrome defined by
COH1 mutations is fairly unspecific, particularly in very young
patients but in older children too. In addition, deletions in
neighbouring genes may affect the phenotype of Cohen
syndrome in the context of a contiguous gene syndrome.
Nevertheless, young patients with a hypotonic facial expres-
sion, almond shaped eyes, short philtrum, mental retardation,
and motor and speech delay are suspicious for Cohen syndrome.
Microarrays have the potential to diagnose Cohen syndrome
in very young patients and in patients with an atypical
phenotype.
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Poetry
The battle of replication fork
Small soldiers march swiftly, the battle draws near
Helicase from the cannons split legions, no fear
Commanders ride forth with bellowing calls
Sending signals to primers, engage, pair them all!
Deoxy stands back, a path must be made
Those RNA boys bear the brunt of the trade
At last help’s arrived; they’ve come through the trees
3-primed and ready, polymerase threes
RNA clears the field, a job nicely done
Their stations soon filled by polymerase one
“Who leads?” cries the general, he asks for a name
It’s 3-prime not 5, the phosphates to blame
Fragmented and lagging are the men from Japan
Send ligase post haste, it’s part of the plan
The fighting drones on, with no end in sight
Gyrase eases tensions, gets men through the night
At last the sun rises, dust settles, all clear
Polymerase checks that the win is sincere
Not a moment for rest, they’re worked to the ground
For over those hills, more ori abound
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